Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ceapro, IR2Dx to work on pre-diabetes screening test

This article was originally published in Clinica

Executive Summary

Canadian biotech firm Ceapro is set to develop its CeaProve point-of-care, pre-diabetes screening test alongside IR2Dx, a company specialising in metabolic diagnostics. The two firms have signed a research and commercial development agreement, which will see a clinical research project established in Germany and Canada to demonstrate CeaProve’s superiority over existing glucose tolerance technology.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT043296

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel